EXEL — EXELIXIS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 939767 ·
Last close
$58.16
Market Cap
$14.41B
52W High
$59.72
52W Low
$33.76
ADV30
2,127,843
Next earnings
2026-10-27
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 628,690,000 | 608,033,000 | 248,414,000 | 212,050,000 | 2,494,234,000 | 281,448,000 | 650,472,000 |
| Mar 2026 | 610,812,000 | 590,859,000 | 251,341,000 | 210,467,000 | 2,593,593,000 | 226,152,000 | 657,845,000 |
| Dec 2025 | 598,663,000 | 572,182,000 | 235,910,000 | 244,528,000 | 2,844,423,000 | 482,488,000 | 683,104,000 |
| Sep 2025 | 597,755,000 | 579,181,000 | 256,356,000 | 193,578,000 | 2,823,547,000 | 376,300,000 | 662,847,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$924,675,000
Investing CF
$249,607,000
Financing CF
$-1,131,882,000
CapEx
$-19,510,000
Dividends Paid
—
Buybacks
$-1,093,929,000
EPS Diluted TTM
$3.01
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-215,794,000
Inventory
$26,605,000
Receivables
$328,947,000
ST Investments
$551,055,000
EBIT TTM
$957,183,000
Pretax Income TTM
$1,003,203,000
Interest Exp TTM
—
Analysts
16
Yahoo Snapshot (yfinance, live)
Total Revenue
$2,435,919,872
EBITDA
$1,020,321,024
Free Cash Flow
$739,715,136
Enterprise Value
$13,232,052,224
Total Cash
$839,385,024
Total Debt
$165,928,992
Shares Out
247,781,692
Trailing EPS
$3.18
Book Value
$7.41
ROE
44.4%
ROA
24.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 2,320,126,000 | 892,701,000 | 782,570,000 | 2,844,423,000 | 683,104,000 | 2,161,319,000 | 884,267,000 |
| Dec 2024 | 2,168,701,000 | 689,949,000 | 521,267,000 | 2,947,690,000 | 703,487,000 | 2,244,203,000 | 699,971,000 |
| Dec 2023 | 1,830,208,000 | 170,885,000 | 207,765,000 | 2,942,357,000 | 678,445,000 | 2,263,912,000 | 333,324,000 |
| Dec 2022 | 1,611,062,000 | 201,484,000 | 182,282,000 | 3,071,489,000 | 583,062,000 | 2,488,427,000 | 362,614,000 |
TTM Snapshot
Revenues TTM
$1,978,647,000
NetIncome TTM
$351,840,000
OpCashFlow TTM
$0
Assets (Latest)
$2,844,423,000
Forward EPS
$4.26
Max Pain — expiry 2026-10-16
max pain strike: $55.00 · spot: $58.16 · call oi: 3,638 · put oi: 14,302
Expected Move to 2026-10-16:
±$4.45
(7.65%) —
implied range
$53.71 –
$62.61
· ATM straddle on $60.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.07B | $138.40 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $12.93B | $113.90 | — |
| TWST | Twist Bioscience Corp | $12.12B | $182.83 | — |
| TECH | BIO-TECHNE Corp | $11.39B | $72.61 | — |
| RGEN | REPLIGEN CORP | $10.70B | $189.68 | — |
News headlines (Yahoo Finance, 1h cache)
Could Zanzalintinib's FDA Delay Affect Exelixis' Growth Plans?
2026-09-24 15:48 · Yahoo
Exelixis (EXEL) Faces a Three-Month Zanzalintinib Review Extension. Can the Data Support Approval?
2026-09-17 04:46 · Yahoo
Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle
2026-09-15 11:03 · Yahoo
Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises
2026-09-14 08:02 · Yahoo
EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
2026-09-11 20:19 · Yahoo
Exelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
2026-09-11 20:18 · Yahoo
Exelixis Shares Fall 3.5% as FDA Extends Zanzalintinib Review by Three Months
2026-09-11 13:30 · Yahoo
IBD Stock Of The Day Exelixis Hits Earnings Snag — And Then Breaks Out
2026-09-04 16:55 · Yahoo
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
2026-09-04 15:30 · Yahoo
Cancer Stock Breaks Out To Highs; Key FDA Action On Watch
2026-09-02 17:29 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.